The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to ...

Rapamycin is used to prevent graft rejection in transplant recipients based on its ability to suppress T-cell proliferation. The drug blocks the activity of a protein known as mammalian target of ...

Researchers investigate the sex-dependent microglial response to a colony-stimulating factor 1 receptor (CSF1R) inhibitor.

A groundbreaking review highlights significant advancements in the understanding and treatment of cerebral vascular ...

The researchers used the mTOR inhibitor sirolimus, which was first approved in 1999 to prevent organ rejection after kidney transplants. It had already shown promise in preclinical models of ...

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions ...